Oligomerix, Inc.
PrivateLast Round
Grant
Nov 18, 2023
Total Funding Raised
$14.64M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Oligomerix, Inc. operates in Healthcare & Life Sciences and is based in Bronx, New York. Its latest recorded funding round was a Grant round in November 2023.
Oligomerix, Inc. is a clinical-stage biotechnology company that develops oral, small molecule therapeutics for neurodegenerative diseases such as Alzheimer's by targeting the aggregation of the tau protein.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oligomerix, Inc. Comparables
Compare Oligomerix, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Treventis Corporation | 86% | |
| Asceneuron | 84% | |
| Alzprotect | 81% |
For institutional investors. Book with your work email.
Oligomerix, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 18, 2023 | ||||
| Grant | Aug 9, 2022 | ||||
| Series B Extension | Jun 2, 2022 | ||||
| Grant | Sep 15, 2020 | ||||
| Series B | May 22, 2013 | ||||
Series A | Apr 23, 2012 |
For institutional investors. Book with your work email.
Oligomerix, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Wheatley Partners | Series A |
| NIH RADx | Grant |
| National Institute on Aging | Grant |
| Alzheimer's Drug Discovery Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 63% MoM, reaching 1.5K.
- Jan 26, 2026
Monthly visitors grew 286% MoM, from 235 to 906.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresAug 31, 2026
Oligomerix appoints biopharmaceutical industry veteran Dr. Cara Cassino as interim president and chief executive officer in New York on Aug 31st '26, as it transitions from discovery research to clinical-stage development of its lead Alzheimer's disease candidate.
For institutional investors. Book with your work email.
Oligomerix, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Oligomerix, Inc.'s valuation, stock price, and market status.
Is Oligomerix, Inc. a public or private company?
Oligomerix, Inc. is a private company.
What is the current stock price of Oligomerix, Inc.?
Oligomerix, Inc. is a private company, so its shares have no public market price. Caplight tracks Oligomerix, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Oligomerix, Inc. worth (valuation)?
Valuation information for Oligomerix, Inc. is not publicly available.
Can I buy Oligomerix, Inc. stock?
Oligomerix, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Oligomerix, Inc.'s last funding round?
Oligomerix, Inc.'s most recent funding round was Grant on November 18, 2023.
Who are the main investors in Oligomerix, Inc.?
Key investors in Oligomerix, Inc. include Wheatley Partners.
Will Oligomerix, Inc. IPO soon?
No public IPO plans have been announced for Oligomerix, Inc..
How can I track Oligomerix, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Oligomerix, Inc.'s shares on secondary markets.